Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Baxter
Mallinckrodt
Boehringer Ingelheim

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR BUPRENORPHINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Buprenorphine Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00637000 ↗ Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Completed Indivior Inc. Phase 2 2008-03-01 The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.
New Dosage NCT03608696 ↗ Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Completed Chiesi Farmaceutici S.p.A. Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
New Dosage NCT03608696 ↗ Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Completed Thomas Jefferson University Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Buprenorphine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000200 ↗ Cocaine Effects in Humans: Physiology and Behavior - 1 Completed Columbia University Phase 2 1997-01-01 The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000200 ↗ Cocaine Effects in Humans: Physiology and Behavior - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1997-01-01 The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000202 ↗ Buprenorphine Maintenance for Opioid Addicts - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1988-08-01 The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
NCT00000202 ↗ Buprenorphine Maintenance for Opioid Addicts - 1 Completed Yale University Phase 2 1988-08-01 The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Buprenorphine Hydrochloride

Condition Name

Condition Name for Buprenorphine Hydrochloride
Intervention Trials
Opioid-Related Disorders 94
Opioid-use Disorder 45
Opioid Dependence 37
Opioid Use Disorder 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Buprenorphine Hydrochloride
Intervention Trials
Opioid-Related Disorders 265
Substance-Related Disorders 76
Disease 51
Heroin Dependence 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Buprenorphine Hydrochloride

Trials by Country

Trials by Country for Buprenorphine Hydrochloride
Location Trials
Japan 29
United Kingdom 28
Germany 12
Canada 11
Australia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Buprenorphine Hydrochloride
Location Trials
New York 87
California 74
Pennsylvania 65
Florida 64
Maryland 63
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Buprenorphine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Buprenorphine Hydrochloride
Clinical Trial Phase Trials
Phase 4 88
Phase 3 102
Phase 2/Phase 3 16
[disabled in preview] 123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Buprenorphine Hydrochloride
Clinical Trial Phase Trials
Completed 303
Recruiting 59
Not yet recruiting 35
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Buprenorphine Hydrochloride

Sponsor Name

Sponsor Name for Buprenorphine Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 163
Yale University 36
Indivior Inc. 29
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Buprenorphine Hydrochloride
Sponsor Trials
Other 482
Industry 198
NIH 174
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKinsey
Johnson and Johnson
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.